MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dyskinesias"

  • 2024 International Congress

    Efficacy and Safety of Amantadine in Parkinson’s Disease with Dyskinesia and Motor Fluctuations: A Systematic Review and Meta-Analysis

    S. Rujirussawarawong, S. Aungsumart, C. Kasemsuk, N. Limotai (Bangkok, Thailand)

    Objective: To evaluate the efficacy and safety of oral amantadine (AMA) compared to placebo in the treatment of dyskinesia (DYS) and motor fluctuations (MF) in…
  • 2024 International Congress

    Altered EEG Theta Activity Characterizes Parkinson’s disease with Levodopa-induced Dyskinesia

    M. Sciascia, A. Castelnovo, I. Bertaina, C. Desperati, C. Steadler, A. Kaelin, S. Galati (Lugano, Switzerland)

    Objective: We explored the relationship between the build-up and the downscaling process in patients with Parkinson’s disease by analyzing theta frequency spectral bands. Background: During…
  • 2024 International Congress

    Acute dystonic dyskinesias in a patient used fluvoxamine. Case report

    A. Katok, D. Khasanova, G. Ilina (Kazan, Russian Federation)

    Objective: To represent a case of acute dystonic dyskinesias after fluvoxamine use by the patient with obsessive thoughts and movements. Background: In psychiatric clinical practice,…
  • 2024 International Congress

    Pharmacokinetic-Pharmacodynamic Modeling of Amantadine Extended-Release Capsule Effects on Dyskinesia in Parkinson Disease

    Z. Wang, R. Gomeni, R. Pahwa, R. Hauser, A. Formella, M. Grall, H. Upadhyaya, J. Rubin (Rockville, USA)

    Objective: Evaluate pharmacokinetic/pharmacodynamic (PK/PD) relationships for the delayed- and extended-release (DR/ER) capsule formulation of amantadine [1] in the treatment of levodopa-related dyskinesia in Parkinson disease.…
  • 2024 International Congress

    Genetic Variants and Levodopa Response in Parkinson’s Disease: Insights from MAO-B and DAT1 Polymorphisms

    S. Sarkar, A. Biswas, S. Ansari, S. Sengupta, S. Choudhury, R. Banerjee, S. Chatterjee, S. Dey, H. Kumar (Kolkata, India)

    Objective: This study aimed to find the association of genetic variations between Parkinson’s disease (PD) patients with and without levodopa-induced dyskinesia (LID). we intended to…
  • 2024 International Congress

    Validation of the Kazakh Version of the Movement Disorder Society-Unified Dyskinesia Rating Scale.

    S. Abdraimova, ZH. Myrzayev, A. Karimova, A. Talgatkyzy, T. Khaibullin, G. Kaishibayeva, S. Elubaeva, K. Esembekova, D. Choi, P. Martinez-Martin, C. Goetz, G. Stebbins, SH. Luo, CH. Shashkin, N. Zharkinbekova, R. Kaiyrzhanov (Shymkent, Kazakhstan)

    Objective: This study aimed to validate the Kazakh version of the Movement Disorder Society-Unified Dyskinesia Rating Scale Background: The Unified Dyskinesia Rating Scale (UDysRS) has…
  • 2024 International Congress

    Buspirone/zolmitriptan combination exerts synergistic reduction in dyskinesia without worsening Parkinson disease motor symptomatology

    P. Lewitt, G. Stebbins, K. Christensen, M. Thomsen, R. Tan, A. Pretorius (Detroit, USA)

    Objective: Levodopa-induced dyskinesias (LID) may be amenable to interventions with striatal serotonergic receptors. Preclinical evidence suggests that co-administration of serotonergic agonists with selective receptor properties…
  • 2024 International Congress

    Triple threat: A rare case of a patient with 3 co-existent autoimmune antibodies causing autonomic and movement disorder

    YK. Kim, KC. Colletta (Maywood, USA)

    Objective: We describe a unique case of a patient with a constellation of movement and autonomic abnormalities. Serum paraneoplastic/autoimmune testing was positive for 3 separate…
  • 2024 International Congress

    MOVE-PD: Mapping the Correlation of Sedentary behavior with Motor Symptoms in Parkinson’s Disease

    J. Frederiksen, TH. Thomsen, B. Biering- Sørensen, U. Dalgas, M. Langeskov-Christensen (Glostrup, Denmark)

    Objective: Mapping the correlation between sedentary behavior (SB) and Parkinsons (PD) specific motor symptoms, measured on objective data from wearables. Background: People with Parkinson's (Pwp)…
  • 2024 International Congress

    Levodopa-Entacapone-Carbidopa Intestinal Gel in the treatment of advanced Parkinson’s disease: a two-year experience

    J. Szász, V. Constantin, K. Orbán-Kis, S. Bataga, R. Neagoe, M. Ciorba, I. Mihaly, K. Kelemen, S. Szatmári (Targu Mures, Romania)

    Objective: To evaluate the efficacy of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) in the treatment of patients with advanced Parkinson’s Disease (APD). Background: The continuous enteral infusion…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 40
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • #25116 (not found)
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley